Skip to main content

Patients & Families

The cancer treatments today are available because patients like you agree to participate in a clinical trial

Clinical trials are an important treatment option to consider if you or a loved one is dealing with cancer. Many of the treatments we have in Canada today are available thanks to people like you volunteering to take part in a clinical trial. Not all clinical trials are about drugs or treatments, clinical trials have helped develop screening processes and prevention methods to find better treatments that improve the lives of cancer patients.

CCTG conducts cancer clinical trials that look at the value of exercise and diet, new combinations of drugs as well as emerging therapies in precision medicine and immunotherapies.


Are you considering a cancer clinical trial as part of your treatment path?

There is a list of all of the CCTG trials that are open to patients that can be found here: CCTG Clinical Trials - Public. A complete listing of clinical trials being conducted across Canada, including the locations where they are being conducted, can be found in the searchable database located on this site: Canadian Cancer Trials.

In addition to trials being conducted by CCTG, several other clinical trials being conducted by other groups may also be available. This site has a searchable database of not only CCTG trials but any cancer clinical trial being conducted in Canada, subscribe to their trial alert to o be notified by e-mail when a new trial for a selected type of cancer or location becomes available.

Click for the .pdf:  How to Participate in a Cancer Clinical Trial (pdf)

 

 

 

Who is the Canadian Cancer Trials Group?

The Canadian Cancer Trials Group (CCTG) is a cancer research cooperative group that designs and conducts multidisciplinary clinical trials to improve the practice of medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors. Primary support for CCTG clinical trials conducted across Canada is supported by funding provided by the Canadian Cancer Society.

click for larger image


IND.227 trial were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from a new study show improved survival for patients with pleural mesothelioma

Late-breaking results for the IND.227 trial were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase III international study evaluated the use of the immunotherapy drug pembrolizumab combined with platinum-pemetrexed chemotherapy as a first-line treatment for pleural mesothelioma patients.

More >>
 

CCTG Recruiting for a Patient Representative Volunteer Role

CCTG is currently seeking applications for a Patient Representative for the Hematology Disease Site Committee

More >>
 
 LUMOS2 international trial

CCTG brain cancer trial awarded CCS Breakthrough Grant

Canadian Cancer Society announces details of research funding for low-survival cancers, the CCTG Breakthrough Grant Application lead by Dr Marshall Pitz, has received $ 1,549,130 over 5 years. Brain cancers that are classified as grade 2 or 3 gliomas are incurable and when they recur after treatment, the lack of effective therapies for these hard-to-treat cancers leads to very poor outcomes.

More >>
 

Welcome to new Patient Representative Catherine Wreford

CCTG would like to welcome our new Patient Representative, Catherine Wreford who will be supporting the Brain Cancer Disease Site Committee. Catherine is a professional dancer and actress who was born and raised in Winnipeg, Manitoba, Canada. In 2013, a little over a month after giving birth to her second child, Catherine was diagnosed with incurable anaplastic astrocytoma (a malignant brain tumour).

More >>